Human epididymis protein 4, a novel potential biomarker for diagnostic and prognosis monitoring of lung cancer

Tingting Zhang,Lanhe Chu,Wenchong Tan,Cuiping Ye,Hangming Dong
DOI: https://doi.org/10.1111/crj.13774
2024-05-16
The Clinical Respiratory Journal
Abstract:Our study first used large public databases to analyze the expression of the WFDC2 gene in lung cancer tissues and then compared HE4 with classical tumor markers at the serological level. Finally, western blot and immunohistochemistry were used to detect the expression characteristics of HE4 in lung cancer cells and tissues. Our results show that serum HE4 emerges as a promising novel biomarker for the diagnosis and prognosis assessment of lung cancer. Objective This study aimed to explore the application value of human epididymis protein 4 (HE4) in diagnosing and monitoring the prognosis of lung cancer. Methods First, TCGA (The Cancer Genome Atlas) databases were used to analyze whey‐acidic‐protein 4‐disulfide bond core domain 2 (WFDC2) gene expression levels in lung cancer tissues. Then, a total of 160 individuals were enrolled, categorized into three groups: the lung cancer group (n = 80), the benign lesions group (n = 40), and the healthy controls group (n = 40). Serum HE4 levels and other biomarkers were quantified using an electro‐chemiluminescent immunoassay. Additionally, the expression of HE4 in tissues was analyzed through immunohistochemistry (IHC). In vitro cultures of human airway epithelial (human bronchial epithelial [HBE]) cells and various lung cancer cell lines (SPC/PC9/A594/H520) were utilized to detect HE4 levels via western blot (WB). Results Analysis of the TCGA and UALCAN (The University of Alabama at Birmingham Cancer Data Analysis Portal) databases showed that WFDC2 gene expression levels were upregulated in lung cancer tissues (p
respiratory system
What problem does this paper attempt to address?